SCHEMBL4484758

SCHEMBL4484758

CC1(C)COC(=O)N1c1nc(-c2ccc(C(F)(F)F)cc2)cs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 2/20 0.42
IDH1 O75874 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LTA4H P09960 1/20 0.41
MMP2 P08253 3/20 0.40
AR P10275 4/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
GSTO1 P78417 1/20 0.39
ALOX5 P09917 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076674 0.87 MAPT (0.52) L3MBTL1MEN1KMT2AARALDH1A1
SCHEMBL3975100 0.87 AR (0.57) SIRT5IDH1MEN1KMT2AKDM4E
SCHEMBL4087581 0.85 AR (0.52) SIRT5L3MBTL1MEN1KMT2AKDM4E
SCHEMBL4498531 0.85 ALOX5 (0.41) L3MBTL1MEN1KMT2AKDM4EAR
SCHEMBL4075018 0.84 SMN1; SMN2 (0.51) SIRT5L3MBTL1MEN1KMT2ANPSR1
SCHEMBL4077609 0.84 MAPT (0.52) SIRT5IDH1L3MBTL1MEN1KMT2A
SCHEMBL3977547 0.84 MEN1 (0.48) L3MBTL1MEN1KMT2AKDM4ENPSR1
SCHEMBL4075308 0.84 MEN1 (0.50) L3MBTL1MEN1KMT2AKDM4ENPSR1
SCHEMBL4078198 0.82 AR (0.54) SIRT5L3MBTL1MEN1KMT2AAR
SCHEMBL4077640 0.82 MEN1 (0.38) L3MBTL1MEN1KMT2AKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US claimed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US claimed
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
CN-101501031-A Oxazolidone derivatives as pr modulators WYETH CORP (US) 2009-08-05 CN disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR SIRT5 1031/4885IDH1 971/4885L3MBTL1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.